NeoGenomics Grants Performance Share Units to Officers

TL;DR

**NeoGenomics just granted PSUs to its officers, tying their pay to future performance.**

AI Summary

NeoGenomics, Inc. filed an 8-K on February 23, 2024, reporting on compensatory arrangements for certain officers, specifically the grant of Performance Share Units (PSUs) on February 16, 2024. This filing details the company's executive compensation practices, focusing on performance-based incentives for its leadership.

Why It Matters

This filing provides transparency into how NeoGenomics incentivizes its top executives, which can influence their long-term commitment and performance, ultimately impacting shareholder value.

Risk Assessment

Risk Level: low — The filing primarily concerns routine executive compensation arrangements, which is a standard corporate governance practice.

Key Players & Entities

• NEOGENOMICS INC (company) — registrant
• February 16, 2024 (date) — date of earliest event reported
• February 23, 2024 (date) — filing date
• Nevada (company) — state of incorporation for NeoGenomics, Inc.
• 9490 NeoGenomics Way, Fort Myers, Florida 33912 (company) — principal executive offices address

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share NEO The Nasdaq Stock Market L

Filing Documents

• a8-k2024psuawards.htm (8-K) — 30KB
• a2024psuawardagreement2023.htm (EX-10.1) — 76KB
• 0001077183-24-000016.txt ( ) — 107KB

02 Departure of Directors or Certain Officers Election of Directors Appointment of Certain Officers

Item 5.02 Departure of Directors or Certain Officers Election of Directors Appointment of Certain Officers Compensatory Arrangements of Certain Officers. New Form of Equity Award Agreement under the NeoGenomics Equity Incentive Plan On February 16, 2024, the Culture and Compensation Committee (the Committee ) of the Board of Directors of NeoGenomics, Inc. (the Company ), in its capacity as administrator of the NeoGenomics, Inc. 2023 Equity Incentive Plan effective May 25, 2023 (the 2023 Equity Plan ), authorized and approved the adoption of a new form of equity award agreement under the 2023 Equity Plan to cover awards of performance-based restricted stock units (each, a PSU ) to be granted to eligible award recipients under the 2023 Equity Plan (the PSU Agreement ). The form of PSU Agreement provides for vesting of the underlying restricted stock units in amounts and over periods to be set forth in each PSU Agreement. The form of PSU Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K. The foregoing description of the form of PSU Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit. This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (a) Not applicable (b) Not applicable (c) Not applicable (d) Exhibits. 10.1 F orm of PSU Ag reement under the NeoGenomics, Inc. 2023 Equity Incen tive Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEOGENOMICS, INC. Date February 23, 2024 By s Alicia C. Olivo Alicia C. Olivo EVP, General Counsel Business Development and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR